Literature DB >> 25134728

Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.

Alipi V Naydenov1, Marja D Sepers2, Katie Swinney3, Lynn A Raymond2, Richard D Palmiter4, Nephi Stella5.   

Abstract

Huntington's disease (HD) is caused by an expanded polyglutamine repeat in huntingtin protein that disrupts synaptic function in specific neuronal populations and results in characteristic motor, cognitive and affective deficits. Histopathological hallmarks observed in both HD patients and genetic mouse models include the reduced expression of synaptic proteins, reduced medium spiny neuron (MSN) dendritic spine density and decreased frequency of spontaneous excitatory post-synaptic currents (sEPSCs). Early down-regulation of cannabinoid CB1 receptor expression on MSN (CB1(MSN)) is thought to participate in HD pathogenesis. Here we present a cell-specific genetic rescue of CB1(MSN) in R6/2 mice and report that treatment prevents the reduction of excitatory synaptic markers in the striatum (synaptophysin, vGLUT1 and vGLUT2), of dendritic spine density on MSNs and of MSN sEPSCs, but does not prevent motor impairment. We conclude that loss of excitatory striatal synapses in HD mice is controlled by CB1(MSN) and can be uncoupled from the motor phenotype.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CB1; Dendritic spines; Endocannabinoids; Huntington's disease; R6/2 mice; Synaptic loss

Mesh:

Substances:

Year:  2014        PMID: 25134728      PMCID: PMC4180675          DOI: 10.1016/j.nbd.2014.08.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  27 in total

1.  Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.

Authors:  M Glass; A van Dellen; C Blakemore; A J Hannan; R L M Faull
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 2.  The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.

Authors:  Mauro Maccarrone; Natalia Battista; Diego Centonze
Journal:  Prog Neurobiol       Date:  2007-02-02       Impact factor: 11.685

3.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

Authors:  M Glass; M Dragunow; R L Faull
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

4.  A restricted population of CB1 cannabinoid receptors with neuroprotective activity.

Authors:  Anna Chiarlone; Luigi Bellocchio; Cristina Blázquez; Eva Resel; Edgar Soria-Gómez; Astrid Cannich; José J Ferrero; Onintza Sagredo; Cristina Benito; Julián Romero; José Sánchez-Prieto; Beat Lutz; Javier Fernández-Ruiz; Ismael Galve-Roperh; Manuel Guzmán
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

5.  The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.

Authors:  Ben Woodman; Rachel Butler; Christian Landles; Michelle K Lupton; Jamie Tse; Emma Hockly; Hilary Moffitt; Kirupa Sathasivam; Gillian P Bates
Journal:  Brain Res Bull       Date:  2006-12-05       Impact factor: 4.077

6.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

7.  Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.

Authors:  Ruth Luthi-Carter; Barbara L Apostol; Anthone W Dunah; Molly M DeJohn; Laurie A Farrell; Gillian P Bates; Anne B Young; David G Standaert; Leslie M Thompson; Jang Ho J Cha
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

8.  Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.

Authors:  Tara L Spires; Helen E Grote; Sylvia Garry; Patricia M Cordery; Anton Van Dellen; Colin Blakemore; Anthony J Hannan
Journal:  Eur J Neurosci       Date:  2004-05       Impact factor: 3.386

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

Authors:  Diego Centonze; Silvia Rossi; Chiara Prosperetti; Anne Tscherter; Giorgio Bernardi; Mauro Maccarrone; Paolo Calabresi
Journal:  Biol Psychiatry       Date:  2005-06-15       Impact factor: 13.382

View more
  15 in total

1.  Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Authors:  Robert B Laprairie; Amina M Bagher; Jillian L Rourke; Adel Zrein; Elizabeth A Cairns; Melanie E M Kelly; Christopher J Sinal; Pushkar M Kulkarni; Ganesh A Thakur; Eileen M Denovan-Wright
Journal:  Neuropharmacology       Date:  2019-03-30       Impact factor: 5.250

Review 2.  Molecular insights into cortico-striatal miscommunications in Huntington's disease.

Authors:  Matthew B Veldman; X William Yang
Journal:  Curr Opin Neurobiol       Date:  2017-11-07       Impact factor: 6.627

3.  Dynamic Changes in Synaptic Plasticity Genes in Ipsilateral and Contralateral Inferior Colliculus Following Unilateral Noise-induced Hearing Loss.

Authors:  Senthilvelan Manohar; Francesca Yoshie Russo; Gail M Seigel; Richard Salvi
Journal:  Neuroscience       Date:  2020-04-09       Impact factor: 3.590

4.  Sex-dependent behavioral impairments in the HdhQ350/+ mouse line.

Authors:  Jessica K Cao; Peter J Detloff; Richard G Gardner; Nephi Stella
Journal:  Behav Brain Res       Date:  2017-09-18       Impact factor: 3.332

Review 5.  Endocannabinoid signalling and the deteriorating brain.

Authors:  Vincenzo Di Marzo; Nephi Stella; Andreas Zimmer
Journal:  Nat Rev Neurosci       Date:  2015-01       Impact factor: 34.870

Review 6.  A competitive model for striatal action selection.

Authors:  S Bariselli; W C Fobbs; M C Creed; A V Kravitz
Journal:  Brain Res       Date:  2018-10-06       Impact factor: 3.252

Review 7.  Corticostriatal synaptic adaptations in Huntington's disease.

Authors:  Joshua L Plotkin; D James Surmeier
Journal:  Curr Opin Neurobiol       Date:  2015-02-18       Impact factor: 6.627

8.  The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.

Authors:  Margaret I Davis; Jill R Crittenden; Austin Y Feng; David A Kupferschmidt; Alipi Naydenov; Nephi Stella; Ann M Graybiel; David M Lovinger
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

9.  Control of exploration, motor coordination and amphetamine sensitization by cannabinoid CB1 receptors expressed in medium spiny neurons.

Authors:  Alipi V Bonm; Izaskun Elezgarai; Christina M Gremel; Katie Viray; Nigel S Bamford; Richard D Palmiter; Pedro Grandes; David M Lovinger; Nephi Stella
Journal:  Eur J Neurosci       Date:  2021-07-13       Impact factor: 3.698

10.  Orchestrated activation of mGluR5 and CB1 promotes neuroprotection.

Authors:  Edleusa M L Batista; Juliana G Doria; Talita H Ferreira-Vieira; Juliana Alves-Silva; Stephen S G Ferguson; Fabricio A Moreira; Fabiola M Ribeiro
Journal:  Mol Brain       Date:  2016-08-20       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.